A follow-up study using cancer patients' serum samples taken at different time-points is required to test whether the titer of IgM antibodies against RPPDL biopanning-selected peptides vanishes after surgical removal of the primary tumor and reappears upon tumor recurrence. Here, CD40LG is linked to cancer.